Efficacy of Retreatments With Intravitreal Bevacizumab

Phase 3TerminatedNCT00406744

Asociación para Evitar la Ceguera en México20 enrolled

Overview

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Interventions

Eligibility

Sex: ALLMin age: 60 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \* Any visual acuity * OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid. * Active angiogram leakage Exclusion Criteria: * \* Basal Inflammatory disease * Endoftalmitis history * Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

Efficacy of Retreatments With Intravitreal Bevacizumab

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes